Skip to main content

Table 2 Patients’ responses evaluated at 8 weeks according to the RECIST criteria

From: Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Non-progression rate at 8 weeks (N = 45)
 Rate % (CI 95%) 48.9 (33.7–64.2)
Response at 8 weeks (N = 45)
  N %
 Response at 8 weeks (N = 32)
  Complete response 0 0.0
  Partial response 3 6.7
  Stable disease 19 42.2
  Progressive disease 10 22.2
Not evaluated 8 weeks (N = 13)